1. Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK- Positive Advanced Non–Small-Cell Lung Cancer 
Fiona Blackhall, MD, Dong-Wan Kim, MD, Benjamin Besse, MD, Hiroshi Nokihara, MD, Ji-Youn Han, MD, Keith D. Wilner, PhD, Arlene Reisman, MPH, Shrividya Iyer, PhD, Vera Hirsh, MD, Alice T. Shaw, MD 
Journal of Thoracic Oncology 
Volume 9, Issue 11, Pages (November 2014)
DOI: /JTO
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Differences between-treatment groups in overall change from baseline scores in patient-reported functioning and global QOL. *p < 0.05, **p <
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Differences between-treatment groups in overall change from baseline scores in patient-reported symptoms. *p < 0.05, **p <
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Proportion of patients showing improvement and worsening in functioning, global QOL, and symptoms by treatment subgroup. A, Functioning domains and global QOL. B, Symptoms (EORTC QLQ C-30). C, Lung cancer symptoms (QLQ-LC13). *p < 0.05, **p < 0.001; NS, not significant. All p values are for comparisons versus crizotinib.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

5. FIGURE 4 Time to deterioration in pain in chest, cough, or dyspnea.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions